Abstract

Vascular endothelial growth factor (VEGF) stimulates angiogenesis by binding to VEGF receptor 2 (VEGFR2) on endothelial cells (ECs). Downstream activation of the extracellular related kinases 1/2 (ERK1/2) is important for angiogenesis to proceed. Receptor internalization has been implicated in VEGFR2 signaling, but its role in the activation of ERK1/2 is unclear. To explore this question we utilized pitstop and dynasore, two small molecule inhibitors of endocytosis. First, we confirmed that both inhibitors block the internalization of VEGFR2 in ECs. We then stimulated ECs with VEGF in the presence and absence of the inhibitors and examined VEGFR2 signaling to ERK1/2. Activation of VEGFR2 and C-Raf still occurred in the presence of the inhibitors, whereas the activation of MEK1/2 and ERK1/2 was abrogated. Therefore, although internalization is not required for activation of either VEGFR2 or C-Raf in ECs stimulated with VEGF, internalization is necessary to activate the more distal kinases in the cascade. Importantly, inhibition of internalization also prevented activation of ERK1/2 when ECs were stimulated with other pro-angiogenic growth factors, namely fibroblast growth factor 2 and hepatocyte growth factor. In contrast, the same inhibitors did not block ERK1/2 activation in fibroblasts or cancer cells stimulated with growth factors. Finally, we show that these small molecule inhibitors of endocytosis block angiogenesis in vitro and in vivo. Therefore, receptor internalization may be a generic requirement for pro-angiogenic growth factors to activate ERK1/2 signaling in human ECs, and targeting receptor trafficking may present a therapeutic opportunity to block tumor angiogenesis.

Highlights

  • Growth factor receptors in endothelial cells are an important therapeutic target for anti-angiogenic therapy

  • To confirm that pitstop and dynasore can inhibit the internalization of Vascular endothelial growth factor (VEGF) receptor 2 (VEGFR2) in endothelial cells, we used an “antibody feeding” assay similar to that used to monitor the fate of internalized VEGF receptors in other studies [33, 40, 41, 48]

  • Internalization Is Required for extracellular related kinases 1/2 (ERK1/2) Activation in Stimulated Endothelial Cells but Not in Non-endothelial Cells—We examined whether internalization is required for ERK1/2 activation in endothelial cells stimulated with other pro-angiogenic growth factors, namely fibroblast growth factor 2 (FGF2) and Hepatocyte growth factor (HGF)

Read more

Summary

Background

Growth factor receptors in endothelial cells are an important therapeutic target for anti-angiogenic therapy. Hepatocyte growth factor (HGF) can stimulate angiogenesis by signaling through the MET receptor expressed on endothelial cells [17, 18] Both FGF2 and HGF can mediate resistance to VEGF receptor inhibition by providing an alternative pro-angiogenic signal for endothelial cells (18 –20), and increased tumor expression of both FGF2 and HGF has been linked with resistance to VEGF pathway inhibitors in both preclinical and clinical studies [21,22,23,24]. VEGF, FGF2, and HGF all activate the classical Raf-MEK-ERK signaling cascade This pathway has been reported to exert control on angiogenesis through multiple mechanisms in endothelial cells, including activation of gene transcription, stimulation. We previously showed that pharmacological stimulation of VEGFR2 recycling leads to enhanced endothelial cell migration and angiogenesis in response to VEGF [42] It is still not precisely clear how receptor trafficking in endothelial cells is coupled to the activation of downstream signaling pathways.

EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call